
## Emanuela Fantinel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3319483/publications.pdf Version: 2024-02-01



EMANULELA FANTINEL

#	Article	IF	CITATIONS
1	The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, e645-e653.	1.9	115
2	Metabolic alterations in renal cell carcinoma. Cancer Treatment Reviews, 2015, 41, 767-776.	7.7	71
3	Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. European Urology, 2022, 81, 274-282.	1.9	55
4	De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. Cancer Treatment Reviews, 2018, 70, 67-74.	7.7	41
5	Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. European Journal of Cancer, 2017, 83, 237-246.	2.8	30
6	Cabozantinibâ€related cardiotoxicity: a prospective analysis in a <i>realâ€world</i> cohort of metastatic renal cell carcinoma patients. British Journal of Clinical Pharmacology, 2019, 85, 1283-1289.	2.4	21
7	Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer. Targeted Oncology, 2018, 13, 649-655.	3.6	18
8	Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis. Cancer Treatment Reviews, 2018, 70, 112-117.	7.7	17
9	Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer. Targeted Oncology, 2016, 11, 569-577.	3.6	15
10	Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis. Seminars in Oncology, 2019, 46, 65-72.	2.2	14
11	The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies. Immunotherapy, 2017, 9, 579-587.	2.0	11
12	Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 526.e13-526.e18.	1.6	10
13	PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer. Journal of Immunotherapy, 2019, 42, 269-273.	2.4	10
14	Results of an Italian CORE-IMMUNO study: Safety and clinical-related biomarkers as predictors of immunotherapy (IT) benefit in real-world treatment of various advanced tumors (ATs) Journal of Clinical Oncology, 2019, 37, e14156-e14156.	1.6	9
15	Renal cell carcinoma in one year: Going inside the news of 2017 – A report of the main advances in RCC cancer research. Cancer Treatment Reviews, 2018, 67, 29-33.	7.7	8
16	Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide. Expert Review of Anticancer Therapy, 2015, 15, 1037-1048.	2.4	5
17	Renal Toxicity in Patients Treated with Anti-Pd-1 Targeted Agents for Solid Tumors. Journal of Onco-Nephrology, 2017, 1, 132-142.	0.6	4
18	Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: A case report. Urology Case Reports, 2021, 34, 101444.	0.3	3

#	Article	IF	CITATIONS
19	Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report. Future Science OA, 2015, 1, FSO29.	1.9	2
20	Drug-drug interactions between abiraterone (ABI) or enzalutamide (ENZ) and concomitant medications in patients with metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology, 2016, 27, iv34.	1.2	2
21	Changes in tumor burden and IMDC class after active surveillance (AS) for metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2017, 35, 435-435.	1.6	2
22	Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma. Anti-Cancer Drugs, 2015, 26, 469-473.	1.4	1
23	Impact of dose reduction on survival in patients starting sunitinib (SU) or pazopanib (PA) as first-line for metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2016, 34, 553-553.	1.6	Ο